Galectin-1 regulates tissue exit of specific dendritic cell populations.
Bottom Line: The presence of galectin-1 inhibits migration of immunogenic dendritic cells through the extracellular matrix and across lymphatic endothelial cells, but it has no effect on migration of tolerogenic dendritic cells.The major galectin-1 counter-receptor on both dendritic cell populations is the cell surface mucin CD43; differential core 2 O-glycosylation of CD43 between immunogenic dendritic cells and tolerogenic dendritic cells appears to contribute to the differential effect of galectin-1 on migration.Binding of galectin-1 to immunogenic dendritic cells reduces phosphorylation and activity of the protein-tyrosine kinase Pyk2, an effect that may also contribute to reduced migration of this subset.
Affiliation: From the Departments of Pathology and Laboratory Medicine and.Show MeSH
Related in: MedlinePlus
Mentions: Galectin-1 is expressed by human VECs, and VEC expression of galectin-1 is increased by inflammatory stimuli (38, 39). However, galectin-1 expression by LECs in inflamed human tissue in vivo has not been described. To characterize galectin-1 expression by LECs in inflamed tissue, we examined sections of lymphedematous human skin (Fig. 1). Sections were stained with pAb against human galectin-1 (Fig. 1, top row) or a mAb recognizing the LEC marker podoplanin (Fig. 1, bottom row) (60). In the dermis, galectin-1 was detected in endothelial cells (arrow, top row) lining dilated vessels; these same cells also expressed podoplanin (arrow, bottom row), confirming that the cells were LECs. In addition, there was abundant galectin-1 in the extracellular matrix surrounding lymphatic channels (arrowhead, top right panel). We also detected galectin-1 in infiltrating leukocytes in the dermis.
Affiliation: From the Departments of Pathology and Laboratory Medicine and.